(Q33333315)

25 July 2017

1 reference

title

Heparin-Induced thrombocytopenia: minimising the risks in the elderly patient (English)

1 reference

heparin-induced thrombocytopenia

25 July 2017

1 reference

1 reference

1 reference

Tardy-Poncet B

1

1 reference

25 July 2017

Tardy B

series ordinal

2

1 reference

25 July 2017

publication date

1 May 2000

1 reference

25 July 2017

1 reference

25 July 2017

volume

16

1 reference

25 July 2017

issue

5

1 reference

25 July 2017

page(s)

351-364

1 reference

Platelet aggregation studies for the diagnosis of heparin-induced thrombocytopenia

25 July 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016050-00005

Orgaran (Org 10172): its pharmacological profile in experimental models

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016050-00005

ORG 10172: a low molecular weight heparinoid anticoagulant with a long half-life in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016050-00005

Comparison of the effect of a conventional heparin and a low molecular weight heparinoid on platelet function

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016050-00005

Platelet activation following intravenous injection of a conventional heparin: absence of effect with a low molecular weight heparinoid (Org 10172).

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016050-00005

Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016050-00005

The pathogenesis of venous limb gangrene associated with heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016050-00005

Orgaran in heparin-induced thrombocytopenia

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00002512-200016050-00005

Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia

21 January 2018

1 reference

12 December 2020

Pregnancy complicated by heparin associated thrombocytopenia: management by a prospectively in vitro selected heparinoid (Org 10172).

1 reference

12 December 2020

Heparin-associated thrombocytopenia: immune complexes are attached to the platelet membrane by the negative charge of highly sulphated oligosaccharides

1 reference

12 December 2020

Antibodies from patients with heparin-induced thrombocytopenia/thrombosis are specific for platelet factor 4 complexed with heparin or bound to endothelial cells

1 reference

12 December 2020

Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with orgaran (Org 10172)

1 reference

12 December 2020

1 reference

12 December 2020

Thrombin inhibitors in unstable angina: rebound or continuation of angina after argatroban withdrawal?

1 reference

12 December 2020

Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216).

1 reference

12 December 2020

1 reference

12 December 2020

Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay

1 reference

12 December 2020

Lower limb veins should be systematically explored in patients with isolated heparin-induced thrombocytopenia

1 reference

12 December 2020

Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia.

1 reference

12 December 2020

Automated amidolytic method for determining heparin, a heparinoid, and a low-Mr heparin fragment, based on their anti-Xa activity

1 reference

12 December 2020

A clinical trial of vena caval filters in the prevention of pulmonary embolism in patients with proximal deep-vein thrombosis. Prévention du Risque d'Embolie Pulmonaire par Interruption Cave Study Group

1 reference

12 December 2020

Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia.

1 reference

12 December 2020

Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Heparin-Associated Thrombocytopenia Study (HAT) investigators.

1 reference

12 December 2020

Pentosan polysulfate-induced thrombocytopenia and thrombosis

1 reference

12 December 2020

Anticoagulation with Novastan (argatroban) in patients with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis syndrome

1 reference

12 December 2020

Thrombolytic therapy for pulmonary embolism. Frequency of intracranial hemorrhage and associated risk factors

1 reference

12 December 2020

Effect of Heparin and Heparin Fractions on Platelet Aggregation

1 reference

12 December 2020

Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin

1 reference

12 December 2020

Anticoagulant effects of a low molecular weight heparinoid (Org 10172) in human volunteers and haemodialysis patients

1 reference

12 December 2020

Heparin-induced thrombocytopenia with associated disseminated intravascular coagulation

1 reference

12 December 2020

Thrombopenia and disseminated intravascular coagulation during treatment with heparin: 2 cases with neurological complications

1 reference

12 December 2020

Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism

1 reference

12 December 2020

Heparin-induced thrombocytopenia, thrombosis, and hemorrhage

1 reference

12 December 2020

Surgical management of heparin-associated thrombocytopenia. Strategies in the treatment of venous and arterial thromboembolism

1 reference

12 December 2020

Antigen Generation in Heparin-Associated Thrombocytopenia: The Nonimmunologic Type and the Immunologic Type Are Closely Linked in Their Pathogenesis

1 reference

12 December 2020

Heparin-associated thrombocytopenia in the neurosurgical patient

1 reference

12 December 2020

The heparin-induced thrombocytopenia syndrome: an update.

1 reference

12 December 2020

Failure of Orgaran therapy in a patient with a previous heparin-induced thrombocytopenia syndrome

1 reference

12 December 2020

A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia

1 reference

12 December 2020

Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors

1 reference

12 December 2020

A diagnostic test for heparin-induced thrombocytopenia

1 reference

12 December 2020

Heparin-induced thrombocytopenia with thrombosis: incidence, analysis of risk factors, and clinical outcomes in 108 consecutive patients treated at a single institution

1 reference

12 December 2020

Safety of thrombolytic therapy in elderly patients with massive pulmonary embolism: a comparison with nonelderly patients

1 reference

12 December 2020

1 reference

12 December 2020

Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia

1 reference

12 December 2020

Heparin-induced thrombocytopenia and recurrent thromboembolism

1 reference

12 December 2020

Heparin-induced thrombocytopenia: an under-diagnosed syndrome? Proceedings of a workshop held in London on 1 November 1996

1 reference

12 December 2020

Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia

1 reference

12 December 2020

Heparin induced thrombocytopenia. Variable platelet-rich plasma reactivity to heparin dependent platelet aggregating factor

1 reference

12 December 2020

Heparin-induced thrombocytopenia: cross-reactivity between standard heparin, low molecular weight heparin, dalteparin (Fragmin) and heparinoid, danaparoid (Orgaran).

1 reference

12 December 2020

Heparin-associated thrombocytopenia: isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen

1 reference

12 December 2020

1 reference

12 December 2020

Thrombosis prophylaxis in an AT III deficient pregnant woman: application of a low molecular weight heparinoid

1 reference

12 December 2020

Heparin-associated thrombosis despite normal platelet counts

1 reference

12 December 2020

Heparin-induced thrombocytopenia: laboratory studies

1 reference

12 December 2020

Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172.

1 reference

12 December 2020

Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies

1 reference

12 December 2020

Heparin-induced thrombocytopenia and thrombosis: a potential fatal complication in a routine treatment

1 reference

12 December 2020

The heparin-induced thrombosis-thrombocytopenia syndrome

1 reference

12 December 2020

Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia

1 reference

12 December 2020

Heparin-induced skin lesions

1 reference

12 December 2020

Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety

1 reference

12 December 2020

Fatal danaparoid-sodium induced thrombocytopenia and arterial thromboses

1 reference

12 December 2020

A 14-year study of heparin-induced thrombocytopenia

1 reference

12 December 2020

The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia

1 reference

12 December 2020

Coronary thrombolysis

1 reference

12 December 2020

Immune endothelial-cell injury in heparin-associated thrombocytopenia

1 reference

12 December 2020

Pathogenicity of IgA and/or IgM antibodies to heparin-PF4 complexes in patients with heparin-induced thrombocytopenia

1 reference

12 December 2020

Efficacy and safety of danaparoid sodium (ORG 10172) in critically ill patients with heparin-associated thrombocytopenia

1 reference

12 December 2020

On the role of platelet Fc gamma RIIa phenotype in heparin-induced thrombocytopenia

1 reference

12 December 2020

The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis

1 reference

12 December 2020

10.2165/00002512-200016050-00005

Identifiers

DOI

1 reference

Dimensions Publication ID

25 July 2017

1007529954

0 references

Fatcat ID

release_6dxpfxckszf63m35vw2wtfduia

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/6dxpfxckszf63m35vw2wtfduia

24 November 2022

mapped directly with Wikidata item

1 reference